Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

<p>Abstract</p> <p>Background</p> <p>The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal cancer (mCRC). However,...

Full description

Bibliographic Details
Main Authors: Portales Fabienne, Bachet Jean-Baptiste, Lepère Céline, Boyer-Gestin Christine, Assenat Eric, Mitry Emmanuel, Samalin Emmanuelle, Lièvre Astrid, Vaillant Jean-Nicolas, Ychou Marc, Rougier Philippe
Format: Article
Language:English
Published: BMC 2009-09-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/9/347

Internet

http://www.biomedcentral.com/1471-2407/9/347

Similar Items